Clinical, Translational and Basic Research on Liver Diseases, 2nd Volume
Personalized medicine is a new approach to liver disease management. Liver research over the last decade has shown that response to therapy is variable, hence personalization and identifying factors that will enhance the predictive utility of targeted therapy are critical. There are assays such as the lymphocyte toxicity assay which can identify the hypersensitivity of an individual to drug use or misuse. The knowledge of drug adverse events can save lives and reduce health care costs dramatically. Biomarkers can help identify liver diseases. Cancer immunotherapy, which aims to control the immune system to eradicate cancer, needs to be personalized, because anticancer immune responses can be inhibited in various ways from patient to patient. Cancer immunotherapy includes immune checkpoint inhibitors and monoclonal antibodies, as well as cell therapy, immunogene therapy, and vaccines. Combinations of programmed apoptosis protein 1 (PD-1)/ligand 1 (PD-L1) chemotherapy and radiation therapy, are being explored. Biomarkers are important for predicting the response to immunotherapy in hepatocellular and cholangiocarcinomas. Molecular diagnostics and immunohistochemistry are important technologies for guiding treatment of liver diseases.
The scope of the present Topic is to present the need for:
- The identification of molecular targets as predictive biomarkers is important for matched targeted therapy in alcoholic and non-alcoholic steatohepatitis.
- Constant evaluation of assays to predict and diagnose drug-induced liver injury (DILI).
- Integration of viral-induced liver diseases as a possible co-morbidity of alcohol and drug misuse in liver disease laboratory diagnosis.
- Validation of biomarkers to predict response to combination therapies, including those that characterize the tumor microenvironment and targeted signaling pathways in carcinoma of the liver.
Prof. Dr. Neuman Manuela
Prof. Dr. Stephen Malnick
- personalized medicine
- alcoholic and non-alcoholic fatty liver
- drug interactions and the liver
- molecular triggers for viral disease
|First Decision (median)
Current Issues in Molecular Biology
International Journal of Molecular Sciences
Preprints.org is a multidiscipline platform providing preprint service that is dedicated to sharing your research from the start and empowering your research journey.
MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:
- Immediately share your ideas ahead of publication and establish your research priority;
- Protect your idea from being stolen with this time-stamped preprint article;
- Enhance the exposure and impact of your research;
- Receive feedback from your peers in advance;
- Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.